Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Bergonié
OBJECTIVES:
Primary
* To assess the effect of efavirenz on the PSA non-progression rate at 3 months in patients with castration-refractory metastatic prostate cancer.
Secondary
* To assess the effect of efavirenz on the PSA non-progression rate at 6 months.
* To assess the effect of efavirenz on overall survival.
* To assess the effect of efavirenz on PSA progression-free survival..
* To assess the tolerability and safety profile of efavirenz.
OUTLINE: This is a multicenter study.
Patients receive oral efavirenz once daily in the absence of disease progression or unacceptable toxicity.
Age
18–120
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed prostate cancer
* Metastatic disease
* Castration-refractory disease
No clinical symptoms related to disease progression
